Sapanisertib plus cabozantinib for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies a combination of two drugs for advanced liver cancer with a specific gene change. The goal is to see if adding sapanisertib to the usual cabozantinib treatment helps people live longer without their cancer growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer that is not curable with surgery or other local treatments.
- You have received at least one prior systemic treatment (for the phase 2 part).
- You have measurable disease as defined by imaging criteria.
- You have adequate organ function as shown by blood tests.
- You have a specific change (mutation) in the beta-catenin gene for the phase 2 part.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether atezolizumab combined with a multi-targeted (“multi-kinase”) inhibitor can treat advanced liver cancer that cannot be cured with surgery or local procedures. It focuses on people whose cancer has already grown despite a first-line treatment using atezolizumab plus bevacizumab.
This trial studies a combination treatment for hepatocellular carcinoma (liver cancer) that cannot be removed with surgery or transplant. It adds cabozantinib and immunotherapy (ipilimumab plus nivolumab) to TACE, a procedure that delivers medicine directly to the liver tumor area.
This study is testing a pill called cabozantinib for people with advanced liver cancer (HCC) that has grown despite prior treatment with atezolizumab (Tecentriq) and bevacizumab (Avastin). The goal is to see if cabozantinib can help shrink or slow the cancer.
This trial tests a combination of chemotherapy (Gemox) with two targeted drugs (anlotinib and sintilimab) for people with a rare type of liver cancer that cannot be removed by surgery or has spread. It may offer a new option for patients who have not had systemic treatment or whose first treatment has stopped working.
This trial tests the drug cabozantinib for people with advanced liver cancer (HCC) that has worsened after the first treatment with certain immune therapy combinations. It aims to see if cabozantinib can help control the cancer.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
Hear when a new Advanced Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.